glycoprotein-e2--hepatitis-c-virus has been researched along with Lymphoproliferative-Disorders* in 2 studies
2 other study(ies) available for glycoprotein-e2--hepatitis-c-virus and Lymphoproliferative-Disorders
Article | Year |
---|---|
Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins.
The molecular mechanisms of lymphoproliferation associated with the disruption of interferon (IFN) signaling and chronic hepatitis C virus (HCV) infection are poorly understood. Lymphomas are extrahepatic manifestations of HCV infection; we sought to clarify the molecular mechanisms of these processes.. We established interferon regulatory factor-1-null (irf-1(-/-)) mice with inducible and persistent expression of HCV structural proteins (irf-1/CN2 mice). All the mice (n = 900) were observed for at least 600 days after Cre/loxP switching. Histologic analyses, as well as analyses of lymphoproliferation, sensitivity to Fas-induced apoptosis, colony formation, and cytokine production, were performed. Proteins associated with these processes were also assessed.. Irf-1/CN2 mice had extremely high incidences of lymphomas and lymphoproliferative disorders and displayed increased mortality. Disruption of irf-1 reduced the sensitivity to Fas-induced apoptosis and decreased the levels of caspases-3/7 and caspase-9 messenger RNA species and enzymatic activities. Furthermore, the irf-1/CN2 mice showed decreased activation of caspases-3/7 and caspase-9 and increased levels of interleukin (IL)-2, IL-10, and Bcl-2, as well as increased Bcl-2 expression, which promoted oncogenic transformation of lymphocytes. IL-2 and IL-10 were induced by the HCV core protein in splenocytes.. Disruption of IFN signaling resulted in development of lymphoma, indicating that differential signaling occurs in lymphocytes compared with liver. This mouse model, in which HCV expression and disruption of IFN signaling synergize to promote lymphoproliferation, will be an important tool for the development of therapeutic agents that target the lymphoproliferative pathway. Topics: Age Factors; Animals; Apoptosis; B-Lymphocytes; Caspases; Cell Proliferation; Disease Models, Animal; fas Receptor; Female; Hepacivirus; Hepatitis C, Chronic; Interferon Regulatory Factor-1; Interleukin-10; Interleukin-12; Interleukin-2; Interleukins; Lymphoma; Lymphoproliferative Disorders; Male; Mice; Mice, Knockout; Mice, Transgenic; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Spleen; T-Lymphocytes; Time Factors; Viral Core Proteins; Viral Envelope Proteins; Viral Nonstructural Proteins; Viral Proteins | 2009 |
Genetic heterogeneity of the hypervariable region I of Hepatitis C virus and lymphoproliferative disorders.
B-cell lymphoproliferative disorders (BCLD) have been associated with chronic hepatitis C virus (HCV) infection. The HCV glycoprotein E2 (gpE2) hypervariable region I (HVR-I) may be a potential antigenic candidate to promote B-cell proliferation. The purpose of this study was to analyze the influence of HVR-I sequence variability in the development of BCLD. HVR-I sequences were studied in 29 chronically HCV-infected patients with (n=15) or without (n=14) BCLD. After PCR amplification of the gpE2 region, analysis of the 81 bp HVR-I encoding fragment was performed on 7-18 clones per patient. HVR-I sequence complexity was slightly lower in patients with BCLD (mean 0.347) than without (0.468) (P=0.2), though, sequence diversities were similar (0.0370 vs 0.0954, P=0.239). Phylogenetic analysis did not reveal any BCLD-associated clustering. In our population, neither the recently described insertion between positions 1 and 2 of HVR-I nor residues at positions 4 and 13 were particularly linked to BCLD. As previously described, we confirm the high degree of conservation of HVR-I residues T-2, G-6 and G-23 in our patients. Contrary to recent findings, our analysis based on multiple clones per patient analysis did not reveal any particular motif associated with BCLD. Topics: Adult; Aged; Amino Acid Sequence; B-Lymphocytes; Cell Division; Female; Gene Rearrangement, B-Lymphocyte; Genetic Heterogeneity; Hepacivirus; Hepatitis C, Chronic; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Molecular Sequence Data; Mutation; Phylogeny; Viral Envelope Proteins; Viral Proteins | 2005 |